0.03
+0(+0.00%)
Currency In USD
Address
6714 NW 16th Street
Gainesville, FL
United States of America
Phone
N/A
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
8
First IPO Date
December 18, 2020
| Name | Title | Pay | Year Born |
| Mr. N. Scott Fine | Chief Executive Officer & Director | 569,919 | 1957 |
| Dr. Jeffrey L. Tate Ph.D. | Chief Operating Officer, Chief Quality Officer & Director | 255,138 | 1958 |
| Mr. Joshua M. Fine | Chief Financial Officer & Secretary | 421,174 | 1982 |
| Mr. Michael Eric Lisjak | Senior Vice President of Business Development & Chief Regulatory Officer | 430,402 | 1974 |
| Mr. C. E Strattan | Founder & Director | 0 | 1946 |
| Dr. Karen Mullen FFPM | Interim Chief Medical Officer | 0 | N/A |
| Ms. Lori McKenna | Global Head of Patient Advocacy | 0 | N/A |
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.